Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05797415 | Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers(BLS) | recruiting | — | 25 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06463392 | Deep Learning-based sbORN Diagnostic Model | recruiting | — | 312 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 |
| Oct 1, 2024 |
| clinicaltrials |
| NCT06592755 | Single-Incision Gasless Endoscopic Total Thyroidectomy Via Subclavian Approach Versus Open Surgery for PTC | recruiting | — | 120 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06611150 | Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma | recruiting | Phase 1 | 24 | Sun Yat-sen UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614686 | U87 CAR-T in Patients With Advanced Head and Neck Tumors | recruiting | Phase 1 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06611826 | GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC | not yet recruiting | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 0 | Sep 25, 2024 | clinicaltrials |
| NCT06612697 | Long-term Outcomes of Early-stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone | active not recruiting | — | 262 | Taichung Veterans General HospitalOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06259552 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors(SPX-303) | recruiting | Phase 1 | 232 | SparX Biotech(Jiangsu) Co., Ltd.OTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT05996432 | Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy | recruiting | Early Phase 1 | 48 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06609070 | CHG0521 Oral Coating in Patients with Solid Tissue Tumor/Recurrent/Metastatic TSCC | not yet recruiting | N/A | 30 | Guangzhou University of Traditional Chinese MedicineOTHER | 0 | Sep 23, 2024 | clinicaltrials |
| NCT06137378 | European Larynx Organ Preservation Study (ELOS) [MK-3475-C44](ELOS) | recruiting | Phase 2 | 140 | University of LeipzigOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04718415 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma(OOC-001) | active not recruiting | Phase 2 | 51 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04970134 | Spanish Study for Molecular Characterization of Thyroid Carcinoma(MOLTHY) | active not recruiting | — | 150 | Grupo Español de Tratamiento de Tumores de Cabeza y CuelloOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05517135 | tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella) | recruiting | — | 1,000 | National Cancer Centre, SingaporeOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05724329 | Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) | active not recruiting | Phase 2 | 24 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06248996 | a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients(ARTSCAN VI) | recruiting | Phase 3 | 308 | Lund University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06589609 | Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer | recruiting | Phase 1 | 12 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06599801 | Clinical Outcomes of Thoracodorsal Artery Flap in Oral and Maxillofacial Reconstruction | not yet recruiting | — | 217 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06578871 | Surgery and Reducing Ionizing Radiation of the Unknown Primary(SUPERIOR) | not yet recruiting | Phase 2 | 90 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Sep 3, 2024 | clinicaltrials |
| NCT06575322 | Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma | recruiting | — | 302 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06572514 | De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC | recruiting | Phase 1 / Phase 2 | 20 | Ruijin HospitalOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06007729 | ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 170 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06100497 | Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC | recruiting | Phase 2 | 100 | Beijing Tongren HospitalOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05892354 | Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy | recruiting | N/A | 190 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | recruiting | Phase 2 | 260 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06533267 | Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma. | recruiting | N/A | 442 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06529562 | Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma. | recruiting | N/A | 384 | Ming-Yuan ChenOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06523582 | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients | recruiting | — | 750 | Universidad Nacional Autonoma de MexicoOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT05193617 | Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 104 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06516133 | Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma(OART) | recruiting | Phase 3 | 494 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06383780 | Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. | recruiting | Phase 3 | 90 | XIANG YANQUNOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06438627 | Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial | recruiting | Phase 3 | 164 | XIANG YANQUNOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06301165 | TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 162 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06490341 | GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jul 8, 2024 | clinicaltrials |
| NCT04688528 | Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Positive HNSCC(SEMIRAHN) | recruiting | N/A | 147 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06445088 | Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma | recruiting | — | 908 | Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06455410 | GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 216 | Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05513573 | Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC | active not recruiting | Phase 2 | 75 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06438939 | NBI for Early Diagnosis of OPMD/OSCC(NBI_Oral) | not yet recruiting | N/A | 480 | Cardarelli HospitalOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT05582265 | Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I) | recruiting | Phase 3 | 537 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06323369 | Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 154 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06019130 | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma(NPC-Nivo) | recruiting | Phase 2 | 57 | German Society for Pediatric Oncology and Hematology GPOH gGmbHOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06370026 | KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial | not yet recruiting | Early Phase 1 | 12 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06282497 | Xerostomia-optimised IMRT Versus Standard IMRT in NPC | recruiting | N/A | 524 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06151743 | Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma | recruiting | Phase 2 | 32 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06383507 | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors | not yet recruiting | Phase 1 | 18 | Zhejiang UniversityOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT05931445 | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | active not recruiting | N/A | 500 | Comprehensive Support Project for Oncology ResearchOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06366945 | Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC | not yet recruiting | Phase 2 | 85 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Apr 16, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 1, 2024source: clinicaltrials